ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO506

Efficacy of Empirical Voriconazole vs. Amphotericin B Plus Flucytosine in Peritoneal Dialysis Patients With Fungal Peritonitis (VAF Study): Early Results From a Randomized Controlled Trial

Session Information

Category: Dialysis

  • 702 Dialysis: Home Dialysis and Peritoneal Dialysis


  • Puapatanakul, Pongpratch, Chulalongkorn University, Bangkok, Bangkok, Thailand
  • Tungsanga, Somkanya, Chulalongkorn University, Bangkok, Bangkok, Thailand
  • Kanjanabuch, Talerngsak, Chulalongkorn University, Bangkok, Bangkok, Thailand

Group or Team Name

  • VAF study steering committee

Fungal peritonitis is a rare but life-threatening complication in patients undergoing peritoneal dialysis (PD). we studied the efficacy of two different empirical antifungal regimens for the treatment of PD-related fungal peritonitis.


In a multicenter open-label randomized controlled trial (TCTR20210316001), PD patients aged ≥18 presenting with fungal peritonitis from 18 centers in Thailand were randomized to receive an empirical antifungal regimen of either oral voriconazole (Vz) 6 mg/kg twice daily on day 1 followed by 4 mg/kg twice daily or intravenous amphotericin B (AmB) 1 mg/kg/day plus oral flucytosine (Fluc) 500 mg twice daily, stratified by fungal types (yeast or mold). The PD catheter was removed as soon as possible, and antifungal drugs were continued for at least 14 days after catheter removal and stopped if clinical response was evident. Change in the antifungal drug was allowed upon knowledge of pathogen species but not earlier than 7 days. The primary outcome was mortality at 90 days.


82 PD patients with fungal peritonitis were enrolled (32 [40%] yeast and 48 [60%] mold ) of which 39 and 41 patients received empirical treatment with Vz or AmB plus Fluc, respectively. Empirical drugs resulted in clinical response at 14 days after PD catheter removal, and treatments could be stopped in 87% in Vz group and 83% in AmB plus Fluc group (p=0.59). There was a trend toward a higher mortality rate at 90 days in AmB plus Fluc group compared with Vz group but did not reach statistical significance (Vz 5% vs. AmB plus Fluc 20%, p=0.052). The proportion of patients in whom physicians attempted to resume PD (Vz 28% vs. AmB plus Fluc 29%, p=0.92) and success rate of resuming PD (Vz 82% vs. AmB plus Fluc 83%, p=0.92) were not significantly different between treatment groups. Reversible elevation of serum alkaline phosphatase was documented in 5% of patients in Vz group.


Both empirical antifungal treatment regimens are feasible and well tolerated by PD patients. A trend of superior 90-day survival for treatment with Vz could be attributable to a high incidence of mold peritonitis in this study.


  • Commercial Support –